Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

April 3, 2020

Primary Completion Date

October 9, 2020

Study Completion Date

October 9, 2020

Conditions

Influenza

Interventions

DRUG

Oseltamivir

75 mg capsules orally twice a day from Day 2 to Day 7

BIOLOGICAL

MEDI8852

MEDI8852 is a human IgG1 kappa monoclonal antibody administered as a single IV infusion at either dose 1 or dose 2 on Day 2.

DRUG

Placebo

Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 2.